Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the Medicines and Healthcare products Regulatory Agency plans next to review the list of priority conditions which determine the speed with which applications for licenses for new medicines are considered.

The Medicines and Healthcare products Regulatory Agency (MHRA) does not have a specific list of conditions to which it gives priority when reviewing applications for new medicine licenses. However, it does prioritise applications where there is a public health need, for instance a new medicine which offers a treatment which is not yet available or a generic medicine where there might otherwise be a risk to supply. When deciding whether to prioritise a medicine, the MHRA collaborates with the Department and National Health Service to make sure its decisions align with their priorities.